Nat Rev Cardiol

• 

  Publication Venue For

  • Non-hyperaemic coronary pressure measurements to guide coronary interventions..  17:629-640. 2020
  • Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease..  17:242-257. 2020
  • Cognitive dysfunction in atrial fibrillation..  15:744-756. 2018
  • The epicardium as a hub for heart regeneration..  15:631-647. 2018
  • Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention..  15:480-496. 2018
  • Arrhythmias in 2016: Arrhythmia treatment - evidence catching up with technology..  14:75-76. 2017
  • Antiplatelet therapy: What have we learned from the ANTARCTIC trial?.  13:639-640. 2016
  • Arterial access and arteriotomy site closure devices..  13:641-650. 2016
  • Enhancing the value of clinical trials: the role of data sharing..  13:629-630. 2016
  • Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy..  13:549-559. 2016
  • Acute coronary syndromes in women and men..  13:471-480. 2016
  • Assessing quality-of-life outcomes in cardiovascular clinical research..  13:286-308. 2016
  • Biomarkers: Troponin testing--risk stratification to stratified medicine..  12:625-626. 2015
  • Registry-based randomized clinical trials--a new clinical trial paradigm..  12:312-316. 2015
  • The vulnerable phase after hospitalization for heart failure..  12:220-229. 2015
  • Acute coronary syndromes: Treatment for low-risk patients with STEMI--challenges remain..  11:440-442. 2014
  • Acute coronary syndromes: Right direction--moving proximally in timing of STEMI care..  11:320-321. 2014
  • Acute coronary syndromes. STREAMlining care for patients with STEMI..  10:304-306. 2013
  • Surgery. Translating trials to clinical practice in cardiac surgery..  10:306-307. 2013
  • Acute coronary syndromes: Blood transfusion in patients with acute MI and anaemia..  10:186-187. 2013
  • The disconnect between phase II and phase III trials of drugs for heart failure..  10:85-97. 2013
  • Novel biomarkers in chronic heart failure..  9:347-359. 2012
  • Acute coronary syndromes. Challenging accepted post-MI serum potassium targets..  9:259-260. 2012
  • Oral factor Xa inhibitors for the long-term management of ACS..  9:392-401. 2012
  • The pharmacogenetics of antiplatelet agents: towards personalized therapy?.  8:560-571. 2011
  • Assessment of oral antithrombotic therapy by platelet function testing..  8:572-579. 2011
  • Percutaneous coronary intervention in the elderly..  8:79-90. 2011
  • Antiplatelet therapy: Clopidogrel-PPI interaction, an ongoing controversy..  8:7-8. 2011
  • Risk factors: Anxiety and risk of cardiac events..  7:606-608. 2010
  • Molecular imaging: T2-weighted CMR of the area at risk--a risky business?.  7:547-549. 2010